Viewing a single comment thread. View all comments

burtzev OP t1_j7huvnq wrote

Reply to comment by KetosisMD in Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study by burtzev

One thing strikes me. After the 50% price reduction in early 2022 the wholesale !! price of a one year 'maintenance dose' of Tilavonemab was $28,200. You can be sure that the company is still making money even after halving the price. As of April last year up to 1.5 million people had been treated with the drug. This is in the running for the most successful failure ever.

5

KetosisMD t1_j7i14jt wrote

That’s nuts.

I can’t believe anyone prescribed dangerous placebos.

It’s hard to know what is more broken the FDA or Healthcare

Edit

> 1.5 million treated

No, 1.5 million would be eligible. CMS denied coverage to anyone who isn’t in a trial.

This is good news. I was hoping CMS would pass on this drug and they did.

8

burtzev OP t1_j7i8181 wrote

I believe you are right and that I misread the NYT article.

3

Xinlitik t1_j7ilsea wrote

Why is CMS paying for trial drugs? I thought pharma companies paid for trials- isnt that their excuse for price gouging after the trial is done?

1

KetosisMD t1_j7im6t0 wrote

You’d think !

The trials will fail. All these new Alzheimer’s drugs are garbage.

2

---LJY--- t1_j7knjo2 wrote

Any promising ones?

1

KetosisMD t1_j7lcj13 wrote

Absolutely zero.

it’s all prevention:

Everything that’s good for the heart is good for the brain.

1